CJC-1295 with DAC (5mg)

Long-acting GHRH analog engineered for research precision and stability.

• CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide designed to extend the biological half-life of GHRH analogs in research environments.
• Formulated to support studies on growth hormone (GH) pulsatility, IGF-1 modulation, and endocrine peptide signaling.
• Independently verified by Vanguard Laboratory for purity, composition, and sequence accuracy.

CJC-1295 with DAC incorporates a Drug Affinity Complex that allows reversible albumin binding, significantly extending peptide half-life and enhancing receptor engagement

Studies indicate sustained elevation of GH and IGF-1 levels lasting up to six days post-administration in controlled test subjects

This long-acting design allows researchers to explore endocrine modulation and peptide pharmacokinetics under extended exposure models

Regulatory Status: CJC-1295 with DAC is not FDA-approved for human or veterinary use and is provided exclusively for research purposes.